Searchable abstracts of presentations at key conferences in endocrinology

ea0077p81 | Neuroendocrinology and Pituitary | SFEBES2021

Is gigantism different from acromegaly in terms of causes of death, comorbidities and treatment? A preliminary retrospective study of 156 UK giants

Kaniuka-Jakubowska Sonia , Abeyaratne Dayakshi , Pal Aparna , Plummer Zoe , Archer Natasha , Ayuk John , Kaszubowski Mariusz , Wass John , Korbonits Marta

Introduction: Although acromegaly and pituitary gigantism have the same pathological cause, they have different disease characteristics.Aim: To study tumour size, treatment course and the most common comorbidities in a population with young-onset acromegaly.Materials and Methods: UK Acromegaly Register (UKAR, 22 centres, 1997-2017) retrospective analysis, enriched with patients from the FIPA-consortium. We defined gigantism as diag...

ea0099p515 | Pituitary and Neuroendocrinology | ECE2024

Body weight in acromegaly – does it make any difference?

Kaniuka-Jakubowska Sonia , higham claire , Davis Jessica , Kearney Tara , Loughrey Paul , Elamin Aisha , Flanagan Daniel , Kaszubowski Mariusz , Ayuk John , M Orme Steve , Wass John

Introduction: IGF-1 dependence on sex is a well-known fact; however, whether IGF-1 is also influenced by body weight is still questionable, and the mechanism of a potential relationship between GH, IGF-1 and body weight is not fully explained. The effect of gender (or rather oestrogens) on IGF-1 is visible in acromegaly - women are diagnosed at an older age than men (approximately 4 years) (potentially by suppressive effect on the axis of GH-IGF-1). The aim of the study was to...